AssetMark’s Castle Biosciences CSTL Stock Holding History
Bought
Maintained
Sold
Other funds holding CSTL
AssetMark's CSTL Position: Q3 2026 in Review
AssetMark increased its Castle Biosciences (CSTL) stake by 24% in Q3 2026, buying an estimated $49.2K and bringing the position to 8,340 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #1368.
AssetMark first reported a position in CSTL in Q4 2020 and has held it in 24 quarters since. 150 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.
- AssetMark held 8,340 shares of Castle Biosciences worth $296K as of Q3 2026.
- AssetMark bought 1,630 Castle Biosciences shares in Q3 2026, an estimated $49.2K.
- Castle Biosciences made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1368 holding.
- AssetMark first reported a position in Castle Biosciences in Q4 2020 and has held it in 24 quarters since.
- 150 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.